Clexio Biosciences
Drug Therapies for Treatment of Neurological Conditions
StartupClexio Biosciences is a Petah Tikva-based startup in the Health Tech & Life Sciences sector, established in 2018. Drug Therapies for Treatment of Neurological Conditions. Clexio Biosciences was founded by Elisabeth Kogan and Menashe Levy. The company has 11-50 employees. Core technologies: Biologicals.
The company follows a B2B business model. Product stage: Clinical Trial.
- StagePre-Funding
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQPetah Tikva
- DistrictCenter District
- Last RoundUndisclosed
Elisabeth Kogan Co-founder & CEO
Menashe LevyCo-founder & CTO
What does Clexio Biosciences do?
Clexio Biosciences is a clinical-stage pharmaceutical company developing CNS therapies designed to address patients unmet needs through a scientifically based fusion of drugs and innovative technologies. Clexios growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including major depressive disorder, Parkinsons disease, pain, and other conditions involving impairment of the neurological system.
Who founded Clexio Biosciences?
Clexio Biosciences was founded in 2018 by Elisabeth Kogan (Co-founder & CEO), Menashe Levy (Co-founder & CTO).
What sector is Clexio Biosciences in?
Clexio Biosciences operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Clexio Biosciences located?
Clexio Biosciences is based in Yegi'a Kapayim St 17, Petah Tikva, Israel, Center District.